A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082
This study is recruiting at 11 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hoffmann-La Roche
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale Cancer Center · New Haven, CT
Florida · 3
- Florida Cancer Specialists - SOUTH - SCRI - PPDS · Fort Myers, FL
- Florida Cancer Specialists - NORTH - SCRI - PPDS · St. Petersburg, FL
- Florida Cancer Specialists - EAST - SCRI - PPDS · West Palm Beach, FL
New York · 4
- NYU Langone Hospital - Long Island · Mineola, NY
- Mount SInai Medical Center · New York, NY
- NYU Cancer Center · New York, NY
- Montefiore Medical Center - Montefiore Medical Park · The Bronx, NY
Texas · 1
- MD Anderson Cancer Center · Houston, TX
Virginia · 2
- Oncology & Hematology Associates of Southwest Virginia, Inc · Blacksburg, VA
- Virginia Oncology Associates · Norfolk, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.